糖尿病视网膜病变市场规模、份额和成长分析（按类型、治疗方法、诊断、给药途径、最终用户、分销管道和地区划分）－2026-2033年产业预测

预计到 2024 年，糖尿病视网膜病变市场规模将达到 101.6 亿美元，到 2025 年将达到 108.6 亿美元，到 2033 年将达到 185.2 亿美元，在预测期（2026-2033 年）内复合年增长率为 6.9%。

由于糖尿病盛行率不断上升、人口老化以及糖尿病相关视力障碍发生率不断增加，糖尿病视网膜病变市场预计将迎来显着增长。主要市场驱动因素包括人们对糖尿病的认识不断提高，以及旨在早期检测和管理的创新产品的推出。长期高血糖导致的视网膜毛细血管损伤凸显了有效监测和生活方式改变以降低风险的紧迫性。儘管采取了预防措施，糖尿病视网膜病变仍可能导致不可逆的视力丧失，因此早期疗育至关重要。各公司正在投资人工智慧驱动的筛检解决方案，例如「Check Eye」专案。此外，不断上涨的医疗保健成本和日益老龄化的人口进一步推动了市场潜力，凸显了在管理糖尿病相关併发症持续保持警惕和加强教育的必要性。

糖尿病视网膜病变市场驱动因素

全球糖尿病视网膜病变市场的主要驱动因素之一是全球糖尿病盛行率的不断上升。随着糖尿病发生率的持续增长，包括糖尿病视网膜病变在内的相关併发症的发生率也随之增加，从而推动了对有效筛检、诊断工具和治疗方法的需求。此外，医疗专业人员和患者对糖尿病视网膜病变的认识不断提高，也促使人们增加对创新治疗方法和技术的投资。随着医疗系统寻求减轻视力丧失的负担并改善患者预后，对早期发现和管理的日益重视正在推动市场成长。

限製糖尿病视网膜病变市场的因素

全球糖尿病视网膜病变市场面临的主要限制因素之一是先进诊断和治疗方案的高昂成本。视网膜成像和雷射治疗等先进技术通常需要大量投资，这限制了患者和医疗服务提供者的获取途径，尤其是在发展中地区。此外，这些创新解决方案的报销难题进一步加剧了经济障碍，导致诊断和治疗延迟。因此，这种经济障碍不仅影响患者的治疗效果，也限制了市场成长，因为医疗系统难以分配足够的资源来有效应对日益增长的糖尿病视网膜病变盛行率。

糖尿病视网膜病变市场趋势

糖尿病视网膜病变市场正呈现出一个显着的趋势，即优先考虑早期发现和及时干预策略。这一转变源于人们对该疾病影响的认识不断提高，以及透过积极措施预防视力丧失的可能性。诊断影像技术的进步在实现快速准确诊断方面发挥关键作用，医疗机构也越来越重视定期筛检计画和宣传活动。这种积极主动的方法不仅改善了患者的预后，还有助于开发标靶治疗，使早期发现成为现代糖尿病视网膜病变管理策略的基石，最终有助于提高患者的生活品质。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析
• 技术分析

全球糖尿病视网膜病变市场规模（按类型及复合年增长率划分）（2026-2033 年）

• 非增殖性糖尿病视网膜病变
• 增殖性糖尿病视网膜病变

全球糖尿病视网膜病变市场规模（依治疗方法及复合年增长率划分）（2026-2033 年）

• 药物治疗
• 基于设备的治疗
• 外科手术
• 其他的

全球糖尿病视网膜病变市场规模（按诊断和复合年增长率划分）（2026-2033 年）

• 萤光造影
• 光同调断层扫瞄
• 其他的

全球糖尿病视网膜病变市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 玻璃体内注射
• 玻璃体内植入
• 眼药水
• 雷射手术
• 其他的

全球糖尿病视网膜病变市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 专科诊所
• 居家医疗
• 其他的

全球糖尿病视网膜病变市场规模（依分销管道划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 网路药房
• 其他的

全球糖尿病视网膜病变市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Bayer AG（Germany）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Oxurion NV（Belgium）
• Sirnaomics（China）
• Alimera Sciences（USA）
• Ampio Pharmaceuticals Inc.（USA）
• Kowa Company Ltd.（Japan）
• Genentech, Inc.（USA）
• Regeneron Pharmaceuticals Inc.（USA）
• Roche Holding AG（Switzerland）
• Allergan PLC（Ireland）
• Pfizer, Inc.（USA）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Heidelberg Engineering GmbH（Germany）
• Optos PLC（UK）
• Canon Inc.（Japan）
• Nidek Co., Ltd.（Japan）
• Bausch+Lomb Incorporated（Canada）

结论与建议

Diabetic Retinopathy Market size was valued at USD 10.16 Billion in 2024 and is poised to grow from USD 10.86 Billion in 2025 to USD 18.52 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The market for diabetic retinopathy is poised for significant growth due to an increasing prevalence of diabetes, an aging population, and a rise in diabetes-related vision issues. Key drivers include heightened awareness of diabetes and the introduction of innovative products aimed at early detection and management. Damage to retinal capillaries from prolonged high blood sugar levels underscores the urgency for effective monitoring and lifestyle modifications to mitigate risks. Despite proactive measures, diabetic retinopathy can lead to irreversible vision loss, highlighting the importance of early interventions. Companies are investing in AI-driven solutions for screening, as exemplified by initiatives like Check Eye. Additionally, escalating healthcare spending and an expanding elderly demographic further stimulate market potential, emphasizing the necessity for ongoing vigilance and education in managing diabetes-related complications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Retinopathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetic Retinopathy Market Segments Analysis

Global Diabetic Retinopathy Market is segmented by Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. Based on Treatment, the market is segmented into Medication, Through Device, Surgery and Others. Based on Diagnosis, the market is segmented into Fluorescein Angiography, Optical Coherence Tomography and Others. Based on Route of Administration, the market is segmented into Oral, Intravitreal Injections, Intravitreal Implants, Topical Eye Drops, Laser Surgery, Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetic Retinopathy Market

One of the key market drivers for the global diabetic retinopathy market is the rising prevalence of diabetes worldwide. As the incidence of diabetes continues to increase, the associated complications, including diabetic retinopathy, become more prevalent, thereby driving demand for effective screening, diagnostic tools, and treatment options. Additionally, heightened awareness of diabetic retinopathy among healthcare providers and patients has spurred investments in innovative therapies and technologies. This enhanced focus on early detection and management fosters growth in the market, as healthcare systems seek to reduce the burden of vision loss and improve patient outcomes.

Restraints in the Diabetic Retinopathy Market

One significant market restraint for the global diabetic retinopathy market is the high cost associated with advanced diagnostic and treatment options. Cutting-edge technologies, including retinal imaging and laser therapies, often require substantial investment, which can limit accessibility for patients and healthcare providers, particularly in developing regions. Additionally, reimbursement challenges for these innovative solutions further exacerbate financial barriers, leading to delayed diagnosis and treatment. Consequently, this economic obstacle not only hampers patient outcomes but also restricts market growth as healthcare systems struggle to allocate adequate resources to combat the rising prevalence of diabetic retinopathy effectively.

Market Trends of the Diabetic Retinopathy Market

The diabetic retinopathy market is witnessing a notable trend towards prioritizing early detection and timely intervention strategies. This shift is driven by heightened awareness of the condition's impact and the potential for preventing vision loss through proactive measures. As healthcare providers emphasize regular screening programs and educational campaigns, advancements in imaging technologies play a crucial role in facilitating quick and accurate diagnosis. This proactive approach not only enhances patient outcomes but also supports the development of targeted therapies, making early detection a cornerstone of modern diabetic retinopathy management strategies, ultimately contributing to improved quality of life for affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis
• Technology Analysis

Global Diabetic Retinopathy Market Size by Type & CAGR (2026-2033)

• Market Overview
• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Global Diabetic Retinopathy Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medication
• Through Device
• Surgery
• Others

Global Diabetic Retinopathy Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Global Diabetic Retinopathy Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intravitreal Injections
• Intravitreal Implants
• Topical Eye Drops
• Laser Surgery
• Others

Global Diabetic Retinopathy Market Size by End-Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Diabetic Retinopathy Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Diabetic Retinopathy Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kowa Company Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heidelberg Engineering GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optos PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb Incorporated (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations